Skip to Main Content

Two big drug makers are challenging a provision in Australian patent law that they argue is “unreasonable,” and the outcome could determine the extent to which the pharmaceutical industry continues to find the Australian market attractive.

In a recent complaint, Bristol Myers Squibb (BMY) and Ono Pharmaceutical (OPHLY) maintain that existing law unfairly restricts the ability of a company to win a five-year patent extension for a product and, moreover, is out of step with the prevailing standards in many other countries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED